ActiBio® Spore-Forming Probiotic
Most probiotics die before they reach your gut. ActiBio® doesn't.
ActiBio® H. coagulans 3bn CFU
Why do most probiotics fail to deliver?
Most probiotic supplements never reach the gut alive. Conventional probiotic strains are fragile - destroyed by stomach acid long before they arrive where they're needed.
How does ActiBio® H. coagulans survive where others don't?
ActiBio® is a spore-forming probiotic - meaning it encases itself before making the journey through the stomach. That spore shields it from stomach acid, heat and environmental damage, allowing it to arrive in the gut alive, active and ready to colonise. Once it reaches the gut, the spore opens and the bacteria gets to work. This is not a conventional probiotic. It is a probiotic engineered for survival.
How does ActiBio® work with the rest of LYMA ID²?
ActiBio® doesn't arrive into an unprepared gut. LYMA ID²'s four multi-length prebiotic fibres - feeding every section of the colon simultaneously - have already created the ideal environment for it to colonise and thrive. The prebiotics are the food source. ActiBio® is what feeds on them. Together with Oleacore®'s cellular protection, Algia™ DHA's brain and heart support and the chelated mineral superstructure, ActiBio® is the final piece of a formula where every ingredient exists to make the others work harder. This is not a collection of ingredients. This is a system.
Most probiotics are destroyed by stomach acid before they ever reach the gut, delivering little to no biological value on arrival
ActiBio® H. coagulans is a spore-forming probiotic, this means it can survive stomach acid, arriving alive and active exactly where it's needed
LYMA ID²'s four multi-length prebiotic fibres create the ideal environment for ActiBio® to colonise and thrive on arrival
At 3 billion CFU per serving, ActiBio® delivers a clinically relevant dose: alive, active and ready to work.
ActiBio® H. coagulans in Detail
3bn CFU
Spore-forming Bacillus coagulans strain
Most probiotic strains are fragile and conventional, destroyed by stomach acid before reaching the gut. Without a supportive mechanism, even the highest CFU count delivers little biological value on arrival.
ActiBio® shelters itself in a spore before its journey through the stomach, surviving stomach acid, arriving alive and colonising a prebiotic environment specifically built to receive it by LYMA ID²'s four multi-length fibres.
Global
Peer-reviewed ActiBio® H. coagulans trials
Your Questions About ActiBio® Spore-Forming Probiotic
Conventional probiotic strains are fragile - destroyed by stomach acid long before they reach the gut. ActiBio® H. coagulans is a spore-forming probiotic, meaning it encases itself in a protective shell before making the journey through the stomach. That spore survives stomach acid, heat and environmental damage, allowing it to arrive in the gut alive and active. 3 billion CFU means nothing if the bacteria are dead on arrival.
ActiBio® doesn't arrive into an unprepared gut. LYMA ID²'s four multi-length prebiotic fibres create the ideal environment for it to thrive. The prebiotics are the food source. ActiBio® is what feeds on them. Together, every ingredient in LYMA ID² is designed to make the others work harder. This is not a collection of ingredients - it is a system.
Bacillus coagulans (H. coagulans) is one of the most studied spore-forming probiotic strains. Its spore-forming properties have been independently validated in peer-reviewed trials, and it has been shown to survive gastric transit and establish effectively when combined with an appropriate prebiotic environment. ActiBio® is a patented, high-quality strain selected by Professor Paul Clayton for its stability, survival rate and scientific credibility.
References
1. Murthy DK, Soman RJ, Soman D, Kishan PV. Testing the immunomodulatory effects of probiotic Bacillus coagulans SNZ 1969® in healthy adults: a randomized, double-blind, placebo-controlled trial. Cureus. 2025;17(10):e94845. https://pmc.ncbi.nlm.nih.gov/articles/PMC12624130/
2. Majeed M, Majeed S, Nagabhushanam K, et al. The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: a randomized, double-blind, placebo-controlled study. Medicine. 2023;102(9). https://pmc.ncbi.nlm.nih.gov/articles/PMC9982755/
3. Mazhar S, Simon A, Khokhlova E, et al. In vitro safety and functional characterization of the novel Bacillus coagulans strain CGI314. Frontiers in Microbiology. 2024;14:1302480. https://pmc.ncbi.nlm.nih.gov/articles/PMC10809412/
4. Tzirogiannis K, Panoutsopoulos G, Drakoulis N, et al. Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial. The Lancet Gastroenterology & Hepatology. 2021;6(10):784–792. https://www.sciencedirect.com/science/article/abs/pii/S2468125321002260
5. Majeed M, Nagabhushanam K, Natarajan S, et al. Comparative evaluation for thermostability and gastrointestinal survival of probiotic Bacillus coagulans MTCC 5856. PLOS ONE. 2021. https://pubmed.ncbi.nlm.nih.gov/33580694/
6. Sanders ME, Merenstein DJ, Reid G, et al. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nature Reviews Gastroenterology & Hepatology. 2019;16:605–616. https://pubmed.ncbi.nlm.nih.gov/31296969/
7. Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. Nature Medicine. 2019;25:716–729. https://pubmed.ncbi.nlm.nih.gov/31061539/
